ライフサイエンスコーパス: isoniazid

1 re anchored by two antibiotics, rifampin and isoniazid.

2 Among these, 1601 (82%) initiated isoniazid.

3 rculosis treatment, including rifampicin and isoniazid.

4 ter systemic challenge with acetaminophen or isoniazid.

5 culosis resistant to at least rifampicin and isoniazid.

6 e same pathway as the established antibiotic isoniazid.

7 zes Mtb in vitro combined with rifampicin or isoniazid.

8 rget as evidenced by the clinical success of isoniazid.

9 first-line chemotherapeutics rifampicin and isoniazid.

10 s both alone and combined with rifampicin or isoniazid.

11 plus on sputa was 4% for rifampin and 2% for isoniazid.

12 -NAD adduct formed by the tuberculosis drug, isoniazid.

13 is the target for the frontline anti-TB drug isoniazid.

14 In children <3 years old, isoniazid 0- to 24-hour area under the concentration-tim

15 QC ranges were established for 11 drugs: isoniazid (0.03 to 0.12 mug/ml), rifampin (0.03 to 0.25

16 Only 32.2% of patients randomized to isoniazid (10/31) and 54.5% of patients randomized to le

17 ontrol regimen (10 mg/kg rifampicin, 5 mg/kg isoniazid, 25 mg/kg pyrazinamide, and 15-20 mg/kg ethamb

18 patients awaiting liver transplantation and isoniazid (300 mg q24h for 9 months) initiated post-tran

19 g patients (n=189) were initially prescribed isoniazid (73%), rifampin (12.7%), or another regimen (1

20 % and 92.3% for rifampin, 100% and 93.8% for isoniazid, 91.6% and 94.4% for ethambutol, and 100% and

21 nd the phenotypic DST results were 94.3% for isoniazid, 98.7% for rifampin, 97.6% for quinolones (ofl

22 BI) with 9 months of self-administered daily isoniazid (9H) has historically been low (<50%) among Ne

23 increase the EBA compared with only removing isoniazid after day 2.

24 to evaluate the possible benefit of removing isoniazid after the first 2 treatment days.

25 lus isoniazid was noninferior to 9 months of isoniazid alone for preventing active TB.

26 eventing active TB, potentially more so than isoniazid alone.

27 or 12 weeks, followed by 14 weeks of 5 mg/kg isoniazid and 10 mg/kg rifampicin per day.

28 ntal treatments were given with oral 5 mg/kg isoniazid and 25 mg/kg pyrazinamide per day for 12 weeks

29 (PY); 0.53 per 100 PY in those who initiated isoniazid and 6.52 per 100 PY for those who did not (adj

30 ity in both solid and liquid mediums for the isoniazid and ethambutol groups, as compared with the co

31 is strongly up-regulated upon treatment with isoniazid and ethambutol is the iniBAC operon.

32 We identified isoniazid and ethionamide resistance mutations on line p

33 h species typing and resistance to rifampin, isoniazid and fluoroquinolone antibiotics.

34 olates, including four that are resistant to isoniazid and one that is resistant to both isoniazid an

35 ) positive CD271(+) BM-MSCs after 90 days of isoniazid and pyrazinamide therapy that rendered animal'

36 for other indications reversed tolerance to isoniazid and rifampicin and slowed intracellular growth

37 ing (DST) assay used to detect resistance to isoniazid and rifampicin in the diagnosis of MDR-TB, has

38 The bactericidal drugs isoniazid and rifampicin kill greater than 99% of expone

39 Acquired isoniazid and rifampicin monoresistance occurred in 1 in

40 We estimated the incidence of acquired isoniazid and rifampicin resistance in rifampicin-suscep

41 The sensitivities and specificities for isoniazid and rifampicin resistance of the tools were hi

42 irmed TB disease with resistance to at least isoniazid and rifampicin.

43 isoniazid and one that is resistant to both isoniazid and rifampicin.

44 combination therapies with 3 to 4 months of isoniazid and rifampicin.

45 nistered daily followed by 4 months of daily isoniazid and rifampicin; a 4-month regimen in which the

46 ambutol for 8 weeks, followed by 18 weeks of isoniazid and rifampin (control group).

47 for recommended critical concentrations for isoniazid and rifampin in commercial broth-based systems

48 ally infected mice exhibit tolerance to both isoniazid and rifampin to a degree proportional to the a

49 sults: 1 in 1909 if initially susceptible to isoniazid and rifampin, 1 in 113 if initially isoniazid

50 e (88.4%) contacts had isolates resistant to isoniazid and rifampin, and 41 (36.6%) contacts had isol

51 rium tuberculosis resistant to at least both isoniazid and rifampin.

52 reatment of TBI with 3 months of once-weekly isoniazid and rifapentine (3HP) administered under direc

53 egimen, 12 weekly doses of directly observed isoniazid and rifapentine (3HP), is as efficacious as 9

54 Participants received once-weekly isoniazid and rifapentine by direct observation, self-ad

55 eatment completion and safety of once-weekly isoniazid and rifapentine by self-administration versus

56 Once-weekly isoniazid and rifapentine for 12 doses is effective but

57 support using self-administered, once-weekly isoniazid and rifapentine to treat latent tuberculosis i

58 exist, including a 12-dose regimen of weekly isoniazid and rifapentine.

59 We estimated that mutations conferring isoniazid and streptomycin resistance in this clone were

60 nd clofazimine followed by 2 mo of rifampin, isoniazid, and clofazimine.

61 these miners, 23,659 (87.2%) started taking isoniazid, and isoniazid was dispensed for 6 months or m

62 or resistance to rifampin, fluoroquinolones, isoniazid, and pyrazinamide and enable the selection of

63 intensively sampled to determine rifampicin, isoniazid, and pyrazinamide plasma concentrations after

64 ed that flutamide, troglitazone, diclofenac, isoniazid, and tamoxifen were reported to have the most

65 of isoniazid plus rifampin and six-months of isoniazid are similarly cost-effective in India, and sho

66 hen 64 patients had been included (31 in the isoniazid arm and 33 in the levofloxacin arm).

67 the mice with the antibiotics rifampicin and isoniazid, as expected, resulted in effective clearance

68 363 mg.h/L, rifampin AUC </= 13 mg.h/L, and isoniazid AUC </= 52 mg.h/L.

69 Three, six and thirty-six-month regimens of isoniazid-based therapy are effective in preventing TB.

70 ivo efficacy equal to the first-line TB drug isoniazid, both as a monotherapy and in combination ther

71 g that was formerly used in conjunction with isoniazid, but removed from the antitubercular chemother

72 the United States has been 9 months of daily isoniazid, but shorter treatment regimens now exist, inc

73 Four weeks of daily rifapentine plus isoniazid can be coadministered with efavirenz without c

74 ween a trialdehyde and the tuberculosis drug isoniazid can form one, two, or three hydrazone connecti

75 de and at least four different antibiotics - isoniazid, chloramphenicol, erythromycin and tetracyclin

76 For patients with isoniazid Cmax >4.6 mg/L, higher isoniazid exposures wer

77 ARS identified negative interactions between isoniazid Cmax and rifampicin Cmax/MIC ratio on 2-month

78 PK/PD analyses using MARS identified isoniazid Cmax and rifampicin Cmax/MIC thresholds below

79 If isoniazid Cmax was <4.6 mg/L and rifampicin Cmax/MIC <28

80 [95% CI, 2.03-10.39]) for 24 weeks of daily isoniazid compared with placebo.

81 s <4.6 mg/L and rifampicin Cmax/MIC <28, the isoniazid concentration had an antagonistic effect on cu

82 t because of the high rates of inappropriate isoniazid-containing regimens, and treatment non-adheren

83 Our results suggest 6 mo of isoniazid cured in a small proportion [estimated proport

84 No patients treated with isoniazid, developed tenosynovitis.

85 e and was continued, along with rifampin and isoniazid, during the continuation phase.

86 Antituberculosis therapy (rifampicin, isoniazid, ethambutol and pyrazinamide) was initiated up

87 (APIs) ampicillin, amoxicillin, rifampicin, isoniazid, ethambutol, and pyrazinamide and also screen

88 The predicted resistance to rifampicin and isoniazid exceeded 90% sensitivity and specificity but w

89 AT2 polymorphism, as a possible surrogate of isoniazid exposure.

90 tients with isoniazid Cmax >4.6 mg/L, higher isoniazid exposures were associated with improved rates

91 ance to four types of antibiotics (rifampin, isoniazid, fluoroquinolones, and aminoglycosides) were a

92 Weekly rifapentine plus isoniazid for 3 months (3HP) is as effective as daily is

93 Compared with placebo, isoniazid for 6 months (odds ratio [OR], 0.64 [95% credi

94 All patients received rifampicin and isoniazid for 6 months reinforced with pyrazinamide and

95 idance: ofloxacin, ethambutol, and high-dose isoniazid for 6 months.

96 for 3 months (3HP) is as effective as daily isoniazid for 9 months (9H) for latent tuberculosis infe

97 a once-weekly combination of rifapentine and isoniazid for treatment of latent tuberculosis infection

98 s necessary to develop a safe alternative to isoniazid for tuberculosis prophylaxis in liver transpla

99 Isoniazid (for prophylaxis or treatment), though, reduce

100 or to the Tugela Ferry outbreak (katG S315T [isoniazid]; gidB 130 bp deletion [streptomycin]; 1957 [9

101 utcome was reported in fewer patients in the isoniazid group (85%) and the ethambutol group (80%) tha

102 dence interval [CI], 1.7 to 10.5) versus the isoniazid group and 11.4 percentage points (97.5% CI, 6.

103 or 17 weeks, followed by 9 weeks of placebo (isoniazid group), and in the third group, we replaced is

104 events reported in 127 patients (19%) in the isoniazid group, 111 (17%) in the ethambutol group, and

105 f rifampin (R) dosages added to a regimen of isoniazid (H) and pyrazinamide (Z) was assessed.

106 onth moxifloxacin regimen (moxifloxacin [M], isoniazid [H], rifampicin [R], pyrazinamide [Z], ethambu

107 Isoniazid had concentration-dependent antagonism with ri

108 de with the first-line antituberculosis drug isoniazid [i.e., isonicotinic acid hydrazide (INH)].

109 Analysis of the direct effect of isoniazid in 10,909 miners showed a reduced incidence of

110 In a medium-prevalence setting, 6 months of isoniazid in HIV-infected patients with positive TST red

111 tion of efavirenz with daily rifapentine and isoniazid in human immunodeficiency virus (HIV)-infected

112 ndomized clinical trial (RCT) of 24 weeks of isoniazid in individuals with pulmonary fibrotic lesions

113 an gold mines, despite the successful use of isoniazid in preventing tuberculosis during treatment.

114 d rifampicin; a 4-month regimen in which the isoniazid in the control regimen was replaced by moxiflo

115 Isoniazid induced a drug-tolerant persister population o

116 s 100% for rifampin (RIF) (14/14), 90.0% for isoniazid (INH) (36/40), 70% for ethambutol (EMB) (7/10)

117 n detecting resistance to rifampin (RMP) and isoniazid (INH) and in detecting multidrug-resistant tub

118 ection of XDR-TB plus resistance to the drug isoniazid (INH) for point-of-care use.

119 Twelve-week rifapentine (RPT)/isoniazid (INH) is effective for LTBI but clinical exper

120 The MTBDRplus assay detected isoniazid (INH) resistance directly from the sputum spec

121 or the rapid detection of rifampin (RIF) and isoniazid (INH) resistance.

122 were 91.7% and 96.6%, respectively, and for isoniazid (INH) they were 70.6% and 99.1%.

123 Here we show that Isoniazid (INH) treatment dramatically reduces Mycobacte

124 Co-therapy with rifampicin (RIF) and isoniazid (INH) used to treat tuberculosis in humans fre

125 CWs diagnosed with LTBI were offered 9-month isoniazid (INH), 4-month rifampin (RIF), weekly rifapent

126 The granuloma is treated with isoniazid (INH), a drug that inhibits the synthesis of m

127 Streptomycin (STR), isoniazid (INH), rifampin (RIF), ethambutol (EMB) (colle

128 notypic drug susceptibility testing (DST) to isoniazid (INH), rifampin (RIF), moxifloxacin (MOX), ofl

129 ) in the presence of its common interference isoniazid (INH), which are both found in drug samples.

130 Isoniazid (INH)-induced hepatotoxicity remains one of th

131 cted within 2 y), and recently infected with isoniazid (INH)-resistant strains.

132 nt and evaluation of a rapid breath test for isoniazid (INH)-sensitive TB based on detection of label

133 by resistance to at least rifampin (RMP) and isoniazid (INH).

134 target of the frontline antitubercular drug isoniazid (INH).

135 ory effects due to the antituberculosis drug isoniazid (INH).

136 e (INH-R), and susceptible to rifampicin and isoniazid (INH-S + RIF-S).

137 (7.0% for rifampin [RIF] and 9.3% for RIF or isoniazid [INH]).

138 Isoniazid is associated with higher rates of hepatotoxic

139 istration of combinations of rifampin (RIF), isoniazid [isonicotinylhydrazine (INH)], pyrazinamide, a

140 We also did this for isoniazid, kanamycin, ofloxacin, rifampicin, and strepto

141 mutations in genes conferring resistance to isoniazid (katG and inhA) and rifampin (rpoB).

142 fampicin <8 mg/L, pyrazinamide <35 mg/L, and isoniazid <3 mg/L.

143 31% for 9 months of daily self-administered isoniazid (maximum dose, 300 mg; 9H-SAT).

144 ekly rifapentine (maximum dose, 900 mg) plus isoniazid (maximum dose, 900 mg) (3HP-DOT) and 31% for 9

145 culosis (Mtb) higher than the clinical agent isoniazid (MIC = 0.37 muM).

146 eline isolates (6.1%; 95% CI, 3.6%-9.6%) had isoniazid monoresistance (13 of 17 had an inhA promoter

147 Isoniazid monoresistance was detected in 5.2% of new cas

148 ntiretroviral therapy, and low prevalence of isoniazid monoresistance were associated with a low freq

149 infected with M tuberculosis; 5 million with isoniazid monoresistance, 2 million with MDR, and 100 00

150 f tuberculosis cases at a country level with isoniazid monoresistance, rifampicin monoresistance, mul

151 ine isolates were retrospectively tested for isoniazid monoresistance.

152 ratory specimens and is able to discriminate isoniazid-monoresistant cases from multidrug-resistant c

153 developed tuberculosis in 2014; 58 000 with isoniazid-monoresistant tuberculosis, 25 000 with MDR tu

154 xists for the efficacy and safety of 6-month isoniazid monotherapy, rifampicin monotherapy, and combi

155 rifamycins may be effective alternatives to isoniazid monotherapy.

156 To inhibit InhA, isoniazid must be activated by the catalase-peroxidase K

157 Substitution of moxifloxacin for isoniazid on day 3 did not increase the EBA compared wit

158 concentration-dependant inhibitory effect of isoniazid on efavirenz clearance.

159 ereas rifampicin resistance evolved prior to isoniazid only twice.

160 a grade 3 AE vs 1 of 493 (0.2%) who received isoniazid only.

161 leted treatment vs 351 of 434 (80.9%) in the isoniazid-only group (P = .003).

162 igher treatment completion rate than did the isoniazid-only group and was safe.

163 vs 3 of 434 (cumulative rate, 0.74%) in the isoniazid-only group, for a difference of -0.74% and an

164 ifapentine and isoniazid was as effective as isoniazid-only treatment for the prevention of tuberculo

165 f cysteine or other small thiols with either isoniazid or rifampicin prevents the formation of drug-t

166 ing p.Ser315Thr, which confers resistance to isoniazid, overwhelmingly arose before mutations that co

167 Low rifampin and isoniazid peak and AUC concentrations preceded all cases

168 We were interested in determining whether isoniazid pharmacokinetic variability was associated wit

169 is BCG or Mtb), were exposed to encapsulated isoniazid-PLGA nanoparticles (NPs) using MA as a targeti

170 Three months of isoniazid plus rifampin and six-months of isoniazid are

171 Short-course directly observed isoniazid plus rifapentine (INH/RPT) combination could h

172 Five genes-rpoB (rifampin), katG (isoniazid), pncA (pyrazinamide), gyrA (ofloxacin/fluoroq

173 Our data suggest that isoniazid preclearance of M. tuberculosis bacilli has li

174 B disease in HIV positive individuals, where isoniazid preventative therapy (IPT) is given to those s

175 is, and 483 of 490 children (99%) started on isoniazid preventative therapy did not develop disease.

176 (95% CI 3.5-7.8) for empirical group and for isoniazid preventive therapy (95% CI 3.4-7.8); absolute

177 med a phase I randomized controlled trial of isoniazid preventive therapy (IPT) before revaccination

178 The World Health Organization recommends isoniazid preventive therapy (IPT) for HIV-positive cont

179 Trials of isoniazid preventive therapy (IPT) for people living wit

180 young child contacts (<5 years) who received isoniazid preventive therapy (IPT) had developed disease

181 sified tuberculosis case finding or prior to isoniazid preventive therapy (IPT) in patients infected

182 Isoniazid preventive therapy (IPT) is recommended as pre

183 Isoniazid preventive therapy (IPT) was prescribed to <1%

184 early antiretroviral therapy (ART), 6-month isoniazid preventive therapy (IPT), or both among HIV-in

185 rticipants were randomly assigned to receive isoniazid preventive therapy (n=662) or placebo (n=667)

186 an help to prioritize active case finding or isoniazid preventive therapy among children exposed to T

187 Isoniazid preventive therapy as an adjunct to ART preven

188 nostics, reducing treatment delay, providing isoniazid preventive therapy continuously to human immun

189 creening, active disease treatment, and mass isoniazid preventive therapy for 9 months during 2006-20

190 gramme scenario, a combination of continuous isoniazid preventive therapy for individuals on antiretr

191 cident cases of tuberculosis; 37 were in the isoniazid preventive therapy group (2.3 per 100 person-y

192 y and empirical tuberculosis therapy) or the isoniazid preventive therapy group (antiretroviral thera

193 ncentrations in 19 of 662 individuals in the isoniazid preventive therapy group and ten of the 667 in

194 rical group and 46 (11%) participants in the isoniazid preventive therapy group.

195 mpirical tuberculosis therapy and 426 to the isoniazid preventive therapy group.

196 rical group and 97 (23%) participants in the isoniazid preventive therapy group.

197 t would reduce early mortality compared with isoniazid preventive therapy in high-burden settings.

198 omparing empirical tuberculosis therapy with isoniazid preventive therapy in HIV-positive outpatients

199 t reduce mortality at 24 weeks compared with isoniazid preventive therapy in outpatient adults with a

200 ion of systematic tuberculosis screening and isoniazid preventive therapy in outpatients with advance

201 protection against tuberculosis provided by isoniazid preventive therapy is not known for human immu

202 Isoniazid preventive therapy is recommended in HIV-posit

203 We aimed to assess the effect of isoniazid preventive therapy on the risk of tuberculosis

204 ly assigned (1:1) patients to receive either isoniazid preventive therapy or a placebo for 12 months

205 ultivariate algorithm that predicts benefit, isoniazid preventive therapy should be recommended to al

206 Isoniazid preventive therapy significantly reduced tuber

207 We noted no evidence that the effect of isoniazid preventive therapy was restricted to patients

208 ve therapy group (antiretroviral therapy and isoniazid preventive therapy).

209 e if they had completed at least 5 months of isoniazid preventive therapy, unless they had completed

210 r-randomized, phased-implementation trial of isoniazid preventive therapy.

211 in 7 years of follow-up for those initiating isoniazid preventive therapy.

212 tment; if not, they were offered 9 months of isoniazid preventive therapy.

213 CWs to be offered antiretroviral therapy and isoniazid preventive therapy.

214 thout prior active tuberculosis were offered isoniazid preventive treatment.

215 277 (43%) had received isoniazid prophylaxis before enrolment.

216 -containing regimen: 2 mo of daily rifampin, isoniazid, pyrazinamide, and clofazimine followed by 2 m

217 TB treatment, i.e., 2 mo of daily rifampin, isoniazid, pyrazinamide, and ethambutol followed by 4 mo

218 In all patients isoniazid, pyrazinamide, and ethambutol were added in st

219 kg daily for 8 weeks (intensive phase), with isoniazid, pyrazinamide, and ethambutol.

220 t treatment arms (63 to rifampicin 35 mg/kg, isoniazid, pyrazinamide, and ethambutol; 59 to rifampici

221 amide, and SQ109; 63 to rifampicin 10 mg/kg, isoniazid, pyrazinamide, and moxifloxacin; and 123 to th

222 azinamide, SQ109; 57 to rifampicin 20 mg/kg, isoniazid, pyrazinamide, and SQ109; 63 to rifampicin 10

223 , and ethambutol; 59 to rifampicin 10 mg/kg, isoniazid, pyrazinamide, SQ109; 57 to rifampicin 20 mg/k

224 s (OR, 0.53 [CrI, 0.36 to 0.78]), rifampicin-isoniazid-pyrazinamide regimens (OR, 0.35 [CrI, 0.19 to

225 m-sulfamethoxazole plus at least 12 weeks of isoniazid-pyridoxine (coformulated with trimethoprim-sul

226 pin(r) TB identification; 60.6% and 100% for isoniazid(r) TB identification; and 75.0% and 98.1% for

227 For isoniazid, rapid genotypic tests for Mycobacterium tuber

228 sion model adjusting for age, CD4 count, and isoniazid receipt, subjects with prior active tuberculos

229 ulosis isolate susceptible to rifampicin and isoniazid recovered <3 months after MDR tuberculosis tre

230 e existed for efficacy of weekly rifapentine-isoniazid regimens compared with no treatment (OR, 0.36

231 R, 0.41 [CrI, 0.18 to 0.86]), and rifampicin-isoniazid regimens for 3 to 4 months (OR, 0.52 [CrI, 0.3

232 s (OR, 0.41 [CrI, 0.19 to 0.85]), rifampicin-isoniazid regimens of 3 to 4 months (OR, 0.53 [CrI, 0.36

233 d 53 previously included studies showed that isoniazid regimens of 6 months (odds ratio [OR], 0.65 [9

234 5% confidence interval [CI], 2.06-14.55) and isoniazid resistance (aHR, 5.91; 95% CI, 2.16-16.16).

235 rs of acquired MDR tuberculosis were initial isoniazid resistance (odds ratio [OR], 19.2; 95% confide

236 We examined the impact of isoniazid resistance and treatment regimen, including us

237 There was no significant association with isoniazid resistance and tSCC or initial treatment outco

238 terium tuberculosis complex and rifampin and isoniazid resistance detection on clinical isolates and

239 Isoniazid resistance evolved before rifampicin resistanc

240 Isoniazid resistance is linked primarily to mutations in

241 98.2) and 96.6% (95% CI, 93.2, 98.6) and for isoniazid resistance they were 62.1% (95% CI, 42.3, 79.3

242 ceptible cases (35 vs 29 days; P = .39), and isoniazid resistance was not associated with tSCC in mul

243 In drug-resistant TB, isoniazid resistance was overwhelmingly the initial resi

244 e 100% and 100%, respectively, and those for isoniazid resistance were 90.7% and 100%.

245 del was used to determine the association of isoniazid resistance with tSCC.

246 estimated a 47% increase in the incidence of isoniazid resistance, a 152% increase in multidrug-resis

247 Relapses were associated with isoniazid resistance, treatment before 2007, and lineage

248 fected patients, in the presence of baseline isoniazid resistance.

249 ts with pulmonary tuberculosis, 59 (25%) had isoniazid resistance.

250 treatment non-adherence, this would generate isoniazid resistance.

251 soniazid and rifampin, 1 in 113 if initially isoniazid resistant, and 1 in 23 if initially rifampicin

252 ere predefined as multidrug resistant (MDR), isoniazid resistant, rifampicin susceptible (INH-R), and

253 Mice were aerosol-infected with an isoniazid-resistant (as a surrogate of multidrug-resista

254 The median tSCC was similar for isoniazid-resistant and -susceptible cases (35 vs 29 day

255 culosis, and suggest there are more cases of isoniazid-resistant and multidrug-resistant (MDR) diseas

256 We found that the isoniazid-resistant katG Ser315Thr mutation occurred mor

257 possible exception of patients infected with isoniazid-resistant M. tuberculosis.

258 Early FQ use was higher in isoniazid-resistant than -susceptible cases (20% vs 10%;

259 Although patients with isoniazid-resistant tuberculosis had a high cure rate, t

260 Although isoniazid-resistant tuberculosis is more common than mul

261 A large isoniazid-resistant tuberculosis outbreak centred on Lon

262 Patients with isoniazid-resistant tuberculosis were treated with regim

263 urrence (n = 3) occurred among patients with isoniazid-resistant tuberculosis.

264 ase, of which 10.9% (95% UI:10.2%-11.8%) was isoniazid-resistant.

265 of three clinically used tuberculosis drugs, isoniazid, rifampicin and streptomycin.

266 egimen that included 2 months of ethambutol, isoniazid, rifampicin, and pyrazinamide administered dai

267 As these regimens omit isoniazid, rifampicin, fluoroquinolones and injectable a

268 the combined use of first line antibiotics (isoniazid, rifampicin, pyrazinamide, and ethambutol) is

269 for drug-susceptible pulmonary tuberculosis, isoniazid, rifampicin, PZA, and ethambutol (HRZE regimen

270 there was high between-child variability of isoniazid, rifampin, and pyrazinamide concentrations: 11

271 Compartmental pharmacokinetic parameters of isoniazid, rifampin, and pyrazinamide were identified fo

272 by these regimens to the standard regimen of isoniazid, rifampin, and pyrazinamide, based on exponent

273 s slower than the standard 3-drug regimen of isoniazid, rifampin, and pyrazinamide.

274 lymorphisms (SNPs) that confer resistance to isoniazid, rifampin, ofloxacin, and moxifloxacin occur t

275 One group of patients received isoniazid, rifampin, pyrazinamide, and ethambutol for 8

276 terilizing and bactericidal effect rates for isoniazid, rifampin, pyrazinamide, and ethambutol were t

277 , 4-month rifampin (RIF), weekly rifapentine/isoniazid (RPT/INH) for 12 weeks, or no treatment.

278 lase KatG, an activating enzyme required for isoniazid sensitivity, and upregulation of WhiB7, a tran

279 We argue that co-trimoxazole and isoniazid should also be combined into a single fixed-do

280 f the outbreak strain acquired resistance to isoniazid, streptomycin and rifampicin by around 1973, i

281 Absence of the isoniazid stress signature in drug-tolerant bacilli indi

282 The isoniazid stress signature was induced by initial drug e

283 ed by vaccination and by giving prophylactic isoniazid to children exposed to infectious adults, alth

284 (IQR, 7.04-15.59 L/hour) during rifapentine/isoniazid treatment (GMR, 1.04 [90% confidence interval,

285 y these mutations or caused by ethambutol or isoniazid treatment may be relieved by iniBAC to increas

286 ophages, the addition of N-acetylcysteine to isoniazid treatment potentiated the killing of Mtb Furth

287 per 100 person-years among miners receiving isoniazid vs. 2.91 cases per 100 person-years among cont

288 ment with the combination of rifapentine and isoniazid was as effective as isoniazid-only treatment f

289 of values before and during rifapentine and isoniazid was calculated.

290 23,659 (87.2%) started taking isoniazid, and isoniazid was dispensed for 6 months or more to 35 to 79

291 hat 3 months of once-weekly rifapentine plus isoniazid was noninferior to 9 months of isoniazid alone

292 for 2 months; or a 6-month regimen in which isoniazid was replaced by daily moxifloxacin for 2 month

293 susceptibility results for both rifampin and isoniazid were seen in 26% of MTBDRplus tests performed

294 Current frontline therapies include the drug isoniazid, which inhibits the essential NADH-dependent e

295 Participants receiving daily rifapentine and isoniazid with efavirenz had pharmacokinetic evaluations

296 group), and in the third group, we replaced isoniazid with moxifloxacin for 17 weeks, followed by 9

297 e risk difference for hepatoxicity comparing isoniazid with rifampin ranged from 3% to 7%, with a poo

298 ethambutol followed by 4 mo of rifampin and isoniazid, with a 4-mo clofazimine-containing regimen: 2

299 tine (3HP), is as efficacious as 9 months of isoniazid, with a greater completion rate (82% vs 69%);

300 essional, for 3 months vs 270 daily doses of isoniazid, without supervision by a health care professi